Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Alliance Pharma posts strong results after audit delay
(Sharecast News) - Alliance Pharma reported strong preliminary results for the year ended 31 December on Wednesday, after an audit delay, driven by a robust second half that led to record sales and expanded underlying profit. The AIM-traded firm said consumer healthcare revenue increased 11% at constant exchange rates (CER) to £136.4m, up 9% on a reported basis, with the Kelo-Cote franchise showing significant recovery in the second half, achieving a 29% revenue increase to £63.2m.
Prescription medicine revenue remained stable at £46.3m.
Non-cash impairments totaled £79.3m, due to lower future cash flow expectations and a higher cost of capital, impacting assets like Amberen, Nizoral, and other smaller assets.
A correction of prior year valuation errors added £28.3m to the 2022 non-cash impairment charges.
Underlying profit before tax rose by 4% to £31.5m, while the reported loss before tax widened to £48.8m, from a restated loss of £23.1m in 2022.
Free cash flow grew 35% to £21.3m, and net debt narrowed to £91.2m, bringing group leverage to 2.05x.
The board said it had paused dividends to prioritise reinvestment for business growth.
Its latest US acquisition, ScarAway, performed strongly with £9.9m in revenue, exceeding expectations.
Internal development projects generated £3.5m in revenue, and e-commerce expansions were planned for 2024.
Operational efficiencies included moving Nizoral manufacturing to Thailand, resulting in cost savings and improved delivery performance.
Environmental initiatives achieved a 48% reduction in scope one and two emissions, with targets set for net zero by 2030 and scope three emissions by 2044.
Alliance Pharma noted that it was re-certified as a 'Great Place To Work' in the UK, US, China, and Singapore.
The board was meanwhile strengthened with several new appointments, including a new chair, Camillo Pane, and a new chief executive officer, Nick Sedgwick.
Additionally, the company successfully appealed a Competition and Markets Authority decision, releasing a £7.9m provision for a potential fine.
"Whilst the audit delay has been unsatisfactory, it has allowed us to implement a more robust intangible valuation review process," said chief financial officer Andrew Franklin.
"Despite the non-cash impairments our portfolio continues to provide a solid platform from which to grow our consumer healthcare brands and generate strong cash flow.
"In 2023, we increased marketing investment, launching award winning advertising campaigns for Kelo-Cote and MacuShield to accelerate organic sales growth whilst bringing new products to market."
Franklin said the company's revenues through e-commerce were building strongly, as it strengthened its network of specialist partners and internal capabilities and entered new geographies.
"We remain confident in our medium to long-term performance as we focus our resources on those market segments in which we already have a strong presence and expertise in order to drive solid organic revenue growth above that of the broader consumer healthcare market."
At 0915 BST, shares in Alliance Pharma were up 7.04% at 38p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.